US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
54.29
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
TG Therapeutics Inc (TGTX) Q1 2021 Earnings Call Transcript
↗
May 10, 2021
TGTX earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Recap: TG Therapeutics Q1 Earnings
↗
May 10, 2021
Shares of TG Therapeutics (NASDAQ:TGTX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were down 43.75% year over year to...
Via
Benzinga
Earnings Scheduled For May 10, 2021
↗
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021
↗
April 20, 2021
Upgrades Compass Point upgraded the previous rating for Newtek Business Services Corp (NASDAQ:NEWT) from Neutral to Buy. For the fourth quarter, Newtek Business Services...
Via
Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
↗
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
↗
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >